British Journal of Pharmacology p. 2399 - 2413 (2018)
Update date:2022-08-05
Topics:
Tadesse, Solomon
Bantie, Laychiluh
Tomusange, Khamis
Yu, Mingfeng
Islam, Saiful
Bykovska, Nataliya
Noll, Benjamin
Zhu, Ge
Li, Peng
Lam, Frankie
Kumarasiri, Malika
Milne, Robert
Wang, Shudong
Background and Purpose: Cyclin D-dependent kinases 4 and 6 (CDK4/6) are crucial regulators of the G1 to S phase transition of the cell cycle and are actively pursued as therapeutic targets in cancer. We sought to discover a novel series of orally bioavailable and highly selective small molecule inhibitors of CDK4/6. Experimental Approach: The discovery of pharmacological inhibitors and optimization for potency, selectivity and drug properties were achieved by iterative chemical synthesis, biochemical screening against a panel of kinases, cell-based assays measuring cellular viability, cell cycle distribution, induction of apoptosis and the level of retinoblastoma tumour suppressor protein (Rb) phosphorylation and E2 factor (E2F)-regulated gene expression and in vitro biopharmaceutical and in vivo pharmacokinetic profiling. Key Results: We discovered several lead compounds that displayed >1000-fold selectivity for CDK4/6 over other members of the CDK family. The lead compounds, 82, 91 and 95, potently inhibited the growth of cancer cells by inducing G1 arrest with a concomitant reduction in the phosphorylation of Rb at S780 and in E2F-regulated gene expression. With a remarkable selectivity for CDK4 over 369 human protein kinases, 91 was identified as a highly potent and orally bioavailable drug candidate. Conclusions and Implications: We have identified unique and new inhibitors of CDK4/6 as potential drug candidates. Compound 91 represents an ideal candidate for further development as targeted cancer therapy.
View MoreNanjing Fayekong Chemcial Co.,Ltd
Contact:86-25-58813444
Address:Rm 1503, Unit 1, Building 5, Zijinnanyuan, Nanjing, Jiangsu, China
JIANGSU GRAND XINYI PHARMACEUTICAL CO.,LTD
website:http://www.xypharm.com/
Contact:+86-515-84383317
Address:Chenli Road,Costal Chemical Area Binhai,Yancheng, Jiangsu,China
Nanjing Vincero International Trading Co.,Ltd
Contact:8618936897229
Address:NO.68, ZhuShan Road, JiangNing WanDa Plaza, Building E Room 1703
JiangXi Keyuan Biopharma Co., LTD.
Contact:+86-563-6833666
Address:Guangde Fine Chemical Zone, Anhui Province, China
Nanjing Norris Pharm Technology Co., Ltd.
Contact:+86-13901585132
Address:2 Qiande Road, Jiangning sciencepark Hi-Tech Zone, Nanjing, P.R.China
Doi:10.1002/jhet.4266
(2021)Doi:10.1134/S1070428011070141
(2011)Doi:10.1021/jo00015a018
(1991)Doi:10.1007/s11172-006-0347-3
(2006)Doi:10.1021/jo01137a020
(1952)Doi:10.1016/S0040-4039(00)70536-3
(1978)